SAVIMS

SAVIMS logo white
Menu

August 2022

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Analysis of Serious Adverse Events Following mRNA COVID-19 Vaccination

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomised trials in adults. Vaccine, 40(40), 5798-5805. https://doi.org/10.1016/j.vaccine.2022.08.036 Summary: This article examines serious adverse events (SAEs) associated with mRNA COVID-19 vaccines (Pfizer and Moderna) reported in […]

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Cardiac-Related Mortality Following COVID-19 Vaccination in Florida

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: SA “Vaccine” Injury Medico-Legal Study-Group. (2022). Exploring the relationship between all-cause and cardiac-related mortality following COVID-19 vaccination or infection in Florida residents: a self-controlled case series study. Summary: This study investigates the risks of all-cause and cardiac-related mortality following COVID-19 vaccinations among Florida residents. It reveals that all participants who died did so within

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Periodic Safety Update Report on COVID-19 mRNA Vaccine (BNT162b2)

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: BioNTech Manufacturing GmbH. (2022). COVID-19 mRNA vaccine (nucleoside modified) Reporting Period Periodic Safety Update Report (PSUR) 3: 19 December 2021 through 18 June 2022. Summary: The third Periodic Safety Update Report (PSUR) for the COVID-19 mRNA vaccine (BNT162b2), also known as COMIRNATY®, covers data from 19 December 2021 to 18 June 2022. It outlines

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Evidence of Vascular Damage from mRNA Vaccines

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Palmer, M., & Bhakdi, S. (2022). Vascular and organ damage induced by mRNA vaccines: Irrefutable proof of causality. doctors4covidethics.org. Summary: This article by Palmer and Bhakdi presents alarming findings regarding the safety of mRNA vaccines, particularly in relation to COVID-19. The authors argue that mRNA vaccines do not remain at the injection site but

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Vascular and Organ Damage Induced by mRNA Vaccines: Causality Evidence

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Palmer, M., & Bhakdi, S. (2022). Vascular and organ damage induced by mRNA vaccines: Irrefutable proof of causality. doctors4covidethics.org. Summary: The article by Palmer and Bhakdi presents compelling evidence regarding the adverse effects of mRNA vaccines, particularly focusing on their widespread distribution and subsequent impact on organ health. Key findings reveal that mRNA vaccines

COVID-19, Ivermectin, Other repurposed substances, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Efficacy of Metformin, Ivermectin, and Fluvoxamine in Early COVID-19 Treatment

| | COVID-19, Ivermectin, Other repurposed substances, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Reference: Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., Siegel, L. K., Klatt, N. R., Odde, D. J., Luke, D. G., Anderson, B., Karger, A. B., Ingraham, N. E., Hartman, K. M., Rao, V.,

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Impact of COVID-19 Vaccination Campaign on Mortality in the USA

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Rancourt, D. G., Baudin, M., & Mercier, J. (2022). COVID-Period Mass Vaccination Campaign and Public Health Disaster in the USA: From age/state-resolved all-cause mortality by time, age-resolved vaccine delivery by time, and socio-geo-economic data. Preprint. Retrieved from https://www.medrxiv.org/ Summary: This article examines the impact of the COVID-19 vaccination campaign on all-cause mortality in the

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomised Trials

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomised trials in adults. Vaccine, 40(5), 649-659. https://doi.org/10.1016/j.vaccine.2022.08.036 Summary: This article assesses serious adverse events (SAEs) associated with mRNA COVID-19 vaccines (Pfizer and Moderna) through a

COVID-19, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Serious Adverse Events Following mRNA COVID-19 Vaccination: An Analysis of Randomised Trials

| | COVID-19, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomised trials in adults. Vaccine, 40(1), 1-9. https://doi.org/10.1016/j.vaccine.2022.08.036 Summary: This article examines the serious adverse events (SAEs) associated with mRNA COVID-19 vaccines (Pfizer and Moderna) as

Scroll to Top